Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55.66 USD | +1.11% | -5.21% | -11.09% |
Apr. 18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
Apr. 17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.09% | 4.72B | |
-0.02% | 42.11B | |
+46.28% | 40.08B | |
+5.04% | 40B | |
-11.32% | 26.87B | |
+5.25% | 24.58B | |
-23.83% | 18.44B | |
-1.62% | 11.94B | |
+22.75% | 11.66B | |
+6.44% | 11.01B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- CRISPR Therapeutics : Barclays Adjusts CRISPR Therapeutics' Price Target to $160 from $140, Keeps Overweight Rating